drugset / Trial / NCT05624268
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Timeline
- Start
- 2023-01-19
- Primary completion
- 2025-05-28
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | — |
Indications
No indication recorded.